Orexigen Therapeutics, Inc. 4
4 · Orexigen Therapeutics, Inc. · Filed Jun 2, 2017
Insider Transaction Report
Form 4
Cannell Thomas R
Chief Commercial Officer
Transactions
- Award
Common Stock
2017-05-31$1.55/sh+2,119$3,284→ 3,882 total
Footnotes (1)
- [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.